A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
Completed · Phase 1 · Has a placebo group
Conditions studied: Atopic Dermatitis
In brief
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.
Key facts
- Study ID
- NCT04271514
- Run by
- RAPT Therapeutics, Inc.
- People needed
- 103
- Starts
- 2019-08-12
- Expected to finish
- 2021-04-26
- Last updated by the study team
- 2021-09-30
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Pinnacle Research Group, LLC — Anniston, Alabama, United States
- Perseverance Research Center LLC — Scottsdale, Arizona, United States
- University Clinical Trials, Inc — San Diego, California, United States
- Lenus Research & Medical Group — Miami, Florida, United States
- ForCare Clinical Research — Tampa, Florida, United States
- Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States
- DelRicht Research — Baton Rouge, Louisiana, United States
- Clinical Trials Management,LLC — Metairie, Louisiana, United States
- MetroBoston Clinical Partners LLC — Brighton, Massachusetts, United States
- Sadick Research Group LLC — New York, New York, United States
- Central Sooner Research — Norman, Oklahoma, United States
- DermResearch, Inc. — Austin, Texas, United States
- Progressive Clinical Research PA — San Antonio, Texas, United States
- PRA — Groningen, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.